Market ExpansionARS Pharmaceuticals' new commercial partnership with ALK is expected to strengthen their financial position with a $145M upfront payment, aiding in the US launch efforts for neffy.
Pediatric Market ExpansionRecent 1 mg neffy pediatric-dose approval and launch significantly expands the addressable market as ~23% of epi prescriptions are in the 15-30 kg weight class.
Product DifferentiationNeffy’s longer shelf life and smaller form factor offer additional differentiation over currently available treatments that will drive both conversion of market share and expansion of the total epinephrine market in the United States.